Mazdutide is the GLP-1 plus glucagon dual agonist developed by Innovent Biologics, with a phase 3 program (GLORY in obesity, DREAMS in type 2 diabetes) run in Chinese adults. It is the second dual agonist of this receptor pair, after survodutide, to reach phase 3 publication, and its trials report some of the highest vomiting rates in the class.
Mechanism and receptor profile
A once-weekly subcutaneous peptide with agonist activity at the GLP-1 and glucagon receptors, described in the 2022 phase 2 title as a GLP-1 and glucagon receptor dual agonist. No label, so no FDA-reviewed mechanism statement.
Regulatory status
No application in Drugs@FDA as of 4 September 2026. Regulatory status in China is outside this site's sources; this entry reports only what the trial record shows.
Trials and their numbers
| Trial | Population and duration | Result | PubMed |
|---|---|---|---|
| GLORY-1 | 610 Chinese adults with obesity or overweight, mean weight 87.2 kg, mean BMI 31.1; 48 weeks | At week 32: -10.09% (4 mg), -12.55% (6 mg) vs +0.45% placebo; at week 48: -11.00%, -14.01% vs +0.30%; 49.5% on 6 mg lost 15% or more at 48 weeks vs 2.0% | 40421736 |
| GLORY-2 | 461 Chinese adults with obesity, 16.1% with type 2 diabetes, mean BMI 34.3; 60 weeks | Weight -16.65% on 9 mg vs -1.50% placebo (difference -15.15 points, 95% CI -17.22 to -13.09); 84.3% vs 33.1% lost 5% or more; vomiting 53.1% vs 1.3%; nausea 46.9% vs 3.2%; discontinuation for adverse events 2.9% vs 0% | 42251595 |
| DREAMS-1 | 731 Chinese adults with type 2 diabetes on oral drugs, against dulaglutide 1.5 mg; 28 weeks | HbA1c difference from dulaglutide -0.24 points (4 mg) and -0.30 points (6 mg), non-inferior and superior; weight difference -3.78% at 4 mg | 41407860 |
The GLORY-1 baseline is worth noticing: a mean BMI of 31.1 and a mean weight of 87.2 kg, far lighter than the STEP or SURMOUNT populations (mean BMI around 38). Percent changes in lighter populations are not interchangeable with percent changes in heavier ones, and the placebo arms gained rather than lost weight.
Adverse events
No label table. From the GLORY-2 abstract at 9 mg: vomiting 53.1% against 1.3%, nausea 46.9% against 3.2%, with 2.9% discontinuing for adverse events. GLORY-1 reports the most frequent events as gastrointestinal without rates in the abstract.
Boxed warning
None; no US label exists.
Manufacturer
Innovent Biologics funded GLORY-1, per the abstract; GLORY-2 and DREAMS-1 belong to the same development program.
Where next
Survodutide is the direct comparison in receptor terms, with a different trial population. The comparison table can put the two dual agonists beside tirzepatide and retatrutide.
Questions people ask
Why is mazdutide on a site about FDA-approved drugs?
Because it is a GLP-1 receptor agonist with completed phase 3 trials, and readers ask about it. Its trials so far were run in China in Chinese adults, and it has no FDA application. The entry exists so the numbers can be read in context rather than in a headline.
How bad was the vomiting in GLORY-2?
The abstract reports vomiting in 53.1% of the 9 mg group against 1.3% on placebo, and nausea in 46.9% against 3.2%. Only 2.9% stopped treatment for adverse events. Both facts are true at once; the events were common and mostly tolerated.
Sources
- Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). N Engl J Med 2025. PubMed 40421736 Accessed September 4, 2026.
- Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity: the GLORY-2 randomized clinical trial. JAMA 2026. PubMed 42251595 Accessed September 4, 2026.
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes (DREAMS-1). Nature 2025. PubMed 41407860 Accessed September 4, 2026.
- Drugs@FDA search (no application for mazdutide on 4 September 2026) Accessed September 4, 2026.
Canonical URL: https://formblendsglp1s.com/agents/mazdutide. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.